MX2024011436A - Metodos y composiciones para el tratamiento de enfermedad de parkinson - Google Patents

Metodos y composiciones para el tratamiento de enfermedad de parkinson

Info

Publication number
MX2024011436A
MX2024011436A MX2024011436A MX2024011436A MX2024011436A MX 2024011436 A MX2024011436 A MX 2024011436A MX 2024011436 A MX2024011436 A MX 2024011436A MX 2024011436 A MX2024011436 A MX 2024011436A MX 2024011436 A MX2024011436 A MX 2024011436A
Authority
MX
Mexico
Prior art keywords
disease
compositions
parkinson
methods
treatment
Prior art date
Application number
MX2024011436A
Other languages
English (en)
Spanish (es)
Inventor
Krystof S Bankiewicz
Adrian P Kells
Laar Amber Van
Massimo S Fiandaca
Original Assignee
Askbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Askbio Inc filed Critical Askbio Inc
Publication of MX2024011436A publication Critical patent/MX2024011436A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2024011436A 2022-03-25 2024-09-18 Metodos y composiciones para el tratamiento de enfermedad de parkinson MX2024011436A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263323830P 2022-03-25 2022-03-25
US202263326236P 2022-03-31 2022-03-31
US202263341841P 2022-05-13 2022-05-13
US202263393196P 2022-07-28 2022-07-28
US202363438164P 2023-01-10 2023-01-10
PCT/US2023/016270 WO2023183594A2 (en) 2022-03-25 2023-03-24 Methods and compositions for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
MX2024011436A true MX2024011436A (es) 2024-11-08

Family

ID=88102133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011436A MX2024011436A (es) 2022-03-25 2024-09-18 Metodos y composiciones para el tratamiento de enfermedad de parkinson

Country Status (10)

Country Link
US (1) US20250222072A1 (https=)
EP (1) EP4499155A4 (https=)
JP (1) JP2025510150A (https=)
KR (1) KR20250006358A (https=)
CN (1) CN119256090A (https=)
AU (1) AU2023240256A1 (https=)
CA (1) CA3255025A1 (https=)
IL (1) IL315725A (https=)
MX (1) MX2024011436A (https=)
WO (1) WO2023183594A2 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530447A (zh) * 2015-02-10 2018-01-02 建新公司 病毒颗粒至纹状体和皮质的增强递送
GB202013940D0 (en) * 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences

Also Published As

Publication number Publication date
JP2025510150A (ja) 2025-04-14
EP4499155A4 (en) 2026-04-01
AU2023240256A1 (en) 2024-11-07
IL315725A (en) 2024-11-01
WO2023183594A2 (en) 2023-09-28
CA3255025A1 (en) 2023-09-28
EP4499155A2 (en) 2025-02-05
WO2023183594A3 (en) 2024-01-18
CN119256090A (zh) 2025-01-03
US20250222072A1 (en) 2025-07-10
KR20250006358A (ko) 2025-01-10

Similar Documents

Publication Publication Date Title
MX2020003995A (es) Nuevas moleculas de acido nucleico artificiales.
CO2021015067A2 (es) Compuestos antivirales que contienen nitrilo
CA2747794A1 (en) Treatment of lung and pulmonary diseases and disorders
JP2023534524A5 (https=)
CL2025000279A1 (es) Arn para prevenir o tratar tuberculosis
CL2019002220A1 (es) Gasotransmisor electroquímico que genera composiciones y métodos de uso de los mismos y apósitos y sistemas de tratamiento que incorpora los mismos.
MX2018008694A (es) Metodos y composiciones para tratar la hiperhidrosis.
AR101871A1 (es) Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos
AR125351A1 (es) Composiciones y métodos para modular la expresión de pnpla3
BR112022019211A2 (pt) Azaspirociclos como moduladores de lipase de monoacilglicerol
MX2024011436A (es) Metodos y composiciones para el tratamiento de enfermedad de parkinson
MX2022012506A (es) Métodos y medios para modificar la hemodinámica en infecciones.
AR122341A1 (es) Método para el tratamiento de cáncer utilizando célula adyuvante artificial (aavc)
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello
MX2018012439A (es) Composiciones y metodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotinico.
AR128711A1 (es) Métodos para tratar carcinoma microcítico de pulmón
CO2022006772A2 (es) Composiciones y métodos para el tratamiento de los trastornos de almacenamiento de glucógeno
AR123998A1 (es) Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden
CL2025001156A1 (es) Uso del anticuerpo biespecífico anti-cldn4/anti-cd137 combinado con inhibidor de señales de pd-1 para tratar cáncer.
MX2025001659A (es) Triptaminas y metodos de tratamiento de trastornos del estado de animo
CL2024003076A1 (es) Composiciones y métodos para la prevención y el tratamiento de la infección por el virus de la rabia
CO2025011162A2 (es) Moléculas de ácido nucleico
AR125301A1 (es) Formulaciones de l-asparaginasa
PE20231182A1 (es) Composiciones antivirales topicas que comprenden acido hialuronico y carragenina
Mozafar et al. Histomorphometric evaluation of allogeneic transplantation of bone marrow mesenchymal stem cells in azoospermic mice model